MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced that a five-year Hatch-Waxman patent term extension has been granted by the U.S. Patent and Trademark Office for the patent covering Aloxi® (palonosetron hydrochloride) Injection.
